All News

This comprehensive approach is what all stakeholders, especially patients and families, need and deserve from their health care system.

The need for additional data on safety and efficacy of medicines both new and old that assess all potential risk factors is ever present, with health system pharmacists at the front lines.

A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.

Pharmacists can play a vital role in educating patients about headaches and can help to limit their impact on the patient.

Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.

Treatment options for individuals impacted with PMS can vary and include lifestyle modifications, medication treatments, and herbal products.

Individuals that are younger in age, Black, have low levels of education, and low income were associated with a lower chance of getting the flu shot each year.

Children with a score of higher than 30 on the CHALF Score scale will need an emergency transplant.

Ronna Hauser from the National Community Pharmacists Association (NCPA), discusses updates regarding reimbursement, pharmacy benefit manager (PBM) reforms, and direct and indirect remuneration (DIR) fees.

Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.

Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.

Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.

Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.

Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.

Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.

Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.

Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.

Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.

Pneumococcal serotype 3 was prevalent regardless of vaccination status, with the most common cases being in those with chronic lung disease.

It is crucial to continue to evolve from dependent prescribing to an independent model, and address barriers with opportunities for change.

Nephrotoxic care can be improved with better risk score assessment and provider education.

Oldest adults should be prioritized for vaccinations as they remain high risk for severe conditions if infected.

Improvements in AI could change the way pharmacists and providers interact with, and care for, patients.

In most patients who are pregnant or may become pregnant, warfarin is contraindicated due to increased risk of adverse fetal outcomes.

On this month's episode, Pharmacy Times covers the Academy of Managed Care Pharmacy Nexus 2023 conference, highlighting the updates on biosimilars.

In an article by The New England Journal of Medicine, the authors discuss how drug companies could delay the approval of new oncology drugs under the IRA, delaying patient care.

Coca notes the importance of precision medicine in CKD risk assessment and describes the potential impact multiple therapies can have on future CKD prediction and treatment in the future.

The principal investigator of the Centre for Cardiovascular Science at the University of Edinburgh notes that enhancing endogenous repair can lead to a breakthrough in AKI treatment.

The increased costs for patients with recurrent hyperkalemia were driven by the increased inpatient medical cost of additional time spent in the hospital following recurrence.

An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.